Centene Is Cheap, Cash-Generative and Re-Rating — A Tactical Long

Hook & thesis

Centene Corporation is behaving like a turnaround stock that has already turned: margins are stabilizing, free cash flow is strong, and the market still prices the company at bargain multiples. At today's price of $65.02, the market cap is about $32.1B while enterprise value sits near $24.1B. With free cash flow of roughly $8.95B and EV/EBITDA near 5.3, the math supports a re-rating should management continue to prioritize margin over member count.

I'm recommending a tactical long: enter at $65.02 with a stop at $59.00 and a primary target of $78.00 over a long-term horizon (180 trading days). This trade is built on the idea that the margin recovery is real, government payment tailwinds (Medicare Advantage rate uplift) and cost actions will allow the business to convert earnings into cash that the market is under-appreciating today.

Business overview - why market participants should care

Centene is a managed health-care company focused on government-sponsored programs: Medicaid, Medicare (including Medicare Advantage), Commercial and a smaller "Other" segment (pharmacy operations, vision/dental, clinical and behavioral health services). Its business is closely tied to public policy and capitation rates, so changes in CMS rules, risk scores and enrollment mix materially move revenue and margins.

Two items matter to investors: membership and margin. Centene's membership fell year-over-year in parts of 2025 (total membership down from 27.9M to 26.27M and ACA marketplace membership fell materially), but management explicitly prioritized margin over member growth. That decision matters because even with lower membership the company can deliver outsized free cash flow if health benefits ratio and operating expenses improve.

What the numbers say

• Market cap: roughly $32.1B; enterprise value: $24.07B.
• Free cash flow: $8.951B - a meaningful FCF stream relative to EV.
• Valuation: EV/EBITDA ~5.32 and price-to-free-cash-flow ~3.59. Price-to-sales ~0.16; price-to-book ~1.42.
• Profitability metrics are mixed: trailing EPS shows a negative figure (EPS = -$10.32) and ROE/ROA are negative, reflecting earlier period losses, reserve adjustments or one-offs. But management guided adjusted EPS above $3.00 for 2026, showing improvement is expected.
• Liquidity/leverage: debt-to-equity ~0.71 and current ratio ~2.34, which together indicate balance sheet capacity to fund operations and buybacks or strategic moves.

Put plainly: the equity is priced for weakness while the company generates real cash. If Centene sustains improved margins and converts that to FCF, the valuation will look anomalously cheap and re-rating is likely.

Valuation framing

Use the enterprise view: EV ≈ $24.07B versus free cash flow ≈ $8.95B implies an EV/FCF under 3.0 and a stock P/FCF of ~3.6. EV/EBITDA at ~5.3 is also low for a large-cap health insurer. Price-to-sales of 0.16 reflects the membership-driven revenue base, but P/S alone understates value when FCF generation is strong.

Historically, large insurers trade at materially higher EV/EBITDA and P/FCF multiples when margins and growth are visible. Here the market seems to be applying a hair-trigger discount for membership volatility and regulatory uncertainty. If margins normalize and guidance is met or exceeded (management expects adjusted EPS > $3.00 for 2026), a move to even mid-single-digit EV/EBITDA multiples expansion should push the stock materially higher from current levels.

Catalysts (what will drive the re-rating)

• CMS Medicare Advantage rate uplift: CMS announced a 2.48% increase in 2027 capitation rates, and when combined with risk score trends this becomes meaningful incremental revenue for Medicare Advantage business lines.
• Management focus on margin: explicit prioritization of profitability over raw membership, including workforce cost actions and separation programs, should lower SG&A and improve operating leverage.
• Stabilization in membership trends: soft enrollment can reverse or stabilize as pandemic-era subsidy dynamics fade and outreach/market tactics adjust.
• Continued strong free cash flow conversion: converting reported operating improvements into FCF will give management optionality to buy back shares or pay down debt, both of which are valuation-positive.
• Quarterly beats and raised guidance: the market responded well to better-than-expected results earlier in 2026, and further beats would quickly narrow the valuation discount.

Trade plan (actionable)

Entry: Buy at $65.02 (current market price).
Stop loss: $59.00 (limit risk if margin recovery stalls or membership shock resumes).
Primary target: $78.00 over a long-term horizon (180 trading days).
Secondary target (optional): $90.00 if margin improvements accelerate and FCF conversion stays elevated.

This trade is intended as a long-term tactical position: hold for long term (180 trading days) to give CMS rate changes, cost actions and membership stabilization time to flow through the P&L and cash flow. You can scale into the position on small intraday weakness; if you want a shorter horizon, treat this as a mid-term idea and reduce position size while keeping the stop tight.

Why these levels?

The $59 stop protects against a re-acceleration of membership losses or a reserve hit that reverses recent margin improvement. The $78 primary target assumes a modest multiple expansion toward sector norms and partial recovery in profitability; it equates to a re-rating that still leaves Centene below many peers but recognizes improved fundamentals. The $90 target is achievable if adjusted EPS moves materially above management's current guidance and cash flow remains strong.

Risks & counterarguments (balanced view)

• Membership erosion can persist. Marketplace membership dropped materially (marketplace 5.626M to 3.582M in Q1 in reported periods). Further declines would pressure revenue and the leverage that drives margin improvement.
• Reserve volatility and one-offs. The negative trailing EPS (-$10.32) indicates prior accounting or reserve hits; more adverse reserve development could wipe out near-term gains and spark a fresh sell-off.
• Regulatory and policy risk. Centene's Medicaid and Medicare businesses are tied to state and federal policy. Changes to capitation rules, risk adjustment or subsidies could reduce margins or increase uncertainty.
• Execution risk on cost actions. Workforce separation programs and other savings initiatives can take time to realize and may come with short-term disruption to care delivery or state relationships, which could depress membership and revenue.
• Market re-rating may be slow. Even with improving cash flow, the re-rating depends on investor sentiment toward managed-care names; a risk-off environment could keep multiples compressed.

Counterargument: The bears will argue that the market is accurately pricing a structurally smaller member base and higher regulatory uncertainty, and that the strong free cash flow figure is distorted by timing of collections, reserve releases or non-recurring items. If those elements reverse or prove unsustainable, Centene's valuation would rightfully remain depressed.

What would change my mind

I will downgrade the trade thesis if any of the following occur: a) membership declines accelerate materially (several quarters of net membership loss beyond current guidance), b) the company reports fresh reserve charges or a significantly worse-than-expected health benefits ratio that erases margin gains, or c) management abandons the margin-first strategy and chases enrollment through unprofitable bids. Conversely, a faster-than-expected conversion of operating improvements into recurring free cash flow, plus a sequence of earnings beats, would strengthen the bullish case and justify adding to the position.

Practical position sizing & monitoring

Given the binary risks here (policy and membership volatility), keep position sizing disciplined. Consider sizing so that the stop at $59 represents a 3-6% portfolio risk depending on your risk tolerance. Monitor key datapoints: quarterly adjusted EPS, health benefits ratio, membership by line (Medicaid vs. marketplace vs. Medicare Advantage), CMS rate actions and FCF prints.

Conclusion

Centene is an actionable long at $65.02 because the company is already generating meaningful free cash flow while the stock trades at conservative multiples. The margin recovery story is credible: management has signaled a margin-first strategy, cost actions are in motion, and CMS rate adjustments provide a tailwind for Medicare Advantage. The primary risks - membership attrition, reserve volatility and policy changes - are real and justify a disciplined stop. For patient, risk-aware traders, the risk/reward favors a tactical long over a 180-trading-day holding period.

Key metrics snapshot

Trade idea: Long Centene (CNC) at $65.02, stop $59.00, target $78.00, horizon long term (180 trading days). Risk: membership and reserve volatility.